Almac Expands ‘Direct to Patient’ Service to Europe

Almac has expanded its Direct to Patient shipping service for clinical trials to EU countries. Launched in the U.S. and Canada in October last year, the Direct to Patient offering guarantees all shipments are delivered direct to patients’ homes on time and without compromising product integrity, providing clinical trial sponsors a more cost effective approach to conduct their studies. Patient compliance, efficiency and experience is also improved as they are offered a flexible and convenient method to participate in trials that suit their personal circumstances.

This home delivery service further enhances the existing end-to-end clinical trial distribution service provided by Almac by coordinating all clinical trial material shipments from clinical sites directly to patient’s homes within the European Union, including temperature and non-temperature controlled materials.

“The success of the service experienced to date across the U.S. and Canada is testament to the upsurge in demand for a more patient-centric method of performing trials and we are pleased to be able to now offer this to European countries,” said Donna Christopher, Almac’s global vice president of operations. “Patient retention is often a significant concern associated with conducting clinical trials and Almac’s innovative Direct to Patient solution offers clear advantages to clinical trial patients and is yet another example of how we can ease the burden for sponsors.”